Neha Vapiwala
@NehaVapiwala
Radiation Oncologist, Dean of Admissions, Mother of 3, Cheerleader of many. Views are my own
ID:1187427134114918401
24-10-2019 17:57:49
219 Tweet
1,2K Takipçi
47 Takip Edilen
You may be eligible to participate in a #prostatecancer study, EA8191/INDICATE, for patients with post-prostatectomy recurrence. Learn more: bit.ly/ea8191indicate #pcsm #ProstateCancerAware cc: @nehavapiwala
Truly enjoyed chatting w UroToday re this nationwide trial seeking to help us & our #ProstateCancer pts understand the clinical benefit of #PET -directed treatment intensification. Trying to put the horse back before the cart! National Cancer Institute JanssenUS Blue Earth Diagnostics
Meet some of the esteemed chairs of #APCCC24 , driving forward the conversation in advanced #prostatecancer . Connect with the forefront of oncology leadership. Visit now: apccc.org/apccc-2024/sci…
#OncologyLeaders aurelius omlin silke gillessen Derya Tilki, MD Neha Vapiwala neal shore
Excited for this collaboration with Zeke Emanuel Neha Vapiwala Mendel.ai testing a Human + NLP collaborative platform to improve the efficiency of eligibility assessment in #clinicaltrials . Penn Medicine - Abramson Cancer Center Penn Cancer Innovation
The ASCO elections are OPEN!! Please take time to help us select the next leaders for this incredible organization! And congrats to Dr. Small - we are in great hands! Conquer Cancer, the ASCO Foundation Sumanta K. Pal, MD, FASCO ASCOPres Eric Winer, MD Cardinale B. Smith Neha Vapiwala Nathan A. Pennell MD, PhD, FASCO
brnw.ch/21wE3KK
Many agree critical questions remain re: clinical value of treating #ProstateCancer seen only on PET. So let’s get some answers & prove that our treatments help #patients more than they hurt ZERO Prostate Cancer UroToday.com
Communities are key to achieving shared goals, regardless of our backgrounds & identities. It’s a privilege to be part of this one. #PCF #HealthEquity UroToday.com
Diligently conducted trial demonstrating #radiotherapy can be a safe & effective tx option for inoperable primary #kidneycancer . Having options matters to #cancer pts - and to all who care for them, regardless of specialty
🧵2/ SABR is a novel treatment for primary #kidneycancer which is non-invasive and has fewer technical limitations than thermal ablation. We tested SABR in a 🦘&🌷phase II trial for primary RCC that was inoperable or high-risk for surgery. The benchmark was 90% control at 1-year.
Do you have #ProstateCancer that has returned after prostatectomy? If so, you may be able to participate in this study of potential new treatment approaches. Learn more about the EA8191/INDICATE study: bit.ly/ea8191indicate #pcsm #ProstateCancer Aware cc: @nehavapiwala
It’s an escalating process - citations, site visit, warning, probation, withdrawal of accreditation. No magic number or formula - 1 serious & persistent citation may be enough. Committee deliberation & decision. Michael Steinberg MD Prajnan Das, MD, MS, MPH
Yet more game (mind?)-changing work from the UK 🙇🏽♀️Kudos to Prof Ananya💙 & team for advancing this discussion & Ashish M. Kamat, MD, MBBS for always engaging. The definition of multi-D professionalism.
We are so excited for our new Medical Physics Residents starting today! Welcome to the UPenn RadOnc Family.
#radiation , #radiotherapy , #radiation therapy, #radiation oncology, #radonc , #radiation therapist #radiation treatment, #medphys , #cyberknife , #radiosurgery , #protontherapy